Related Experiment Video
Updated: Apr 15, 2026
A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
Published on: March 2, 2019
PET/MR in dementia and other neurodegenerative diseases
Henryk Barthel1, Matthias L Schroeter2, Karl-Titus Hoffmann3
1Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany.
Abstract:
The spectrum of neurodegenerative diseases covers the dementias, parkinsonian syndromes, Huntington disease, amyotrophic lateral sclerosis, and prion diseases. In these entities, brain MRI is often used in clinical routine to exclude other pathologies and to demonstrate specific atrophy patterns. [18F]FDG PET delivers early and sensitive readouts of neural tissue loss, and more specific PET tracers currently in use clinically target β-amyloid plaques or dopaminergic deficiency. The recent integration of PET into MR technology offers a new chance to improve early and differential diagnosis of many neurodegenerative diseases. Initial evidence in the literature is available to support this notion. New emerging PET tracers, such as tracers that bind to tau or α-synuclein aggregates, as well as MR techniques, like diffusion-tensor imaging, resting-state functional MRI, and arterial spin labeling, have the potential to broaden the diagnostic capabilities of combined PET/MRI to image dementias, Parkinson disease, and other neurodegenerative diseases. The ultimate goal is to establish combined PET/MRI as a first-line imaging technique to provide, in a one-stop-shop fashion with improved patient comfort, all biomarker information required to increase diagnostic confidence toward specific diagnoses. The technical challenge of accurate PET data attenuation correction within PET/MRI systems needs yet to be solved. Apart from the projected clinical routine applications, future research would need to answer the questions of whether combined brain PET/MRI is able to improve basic research of neurodegenerative diseases and antineurodegeneration drug testing.
Insights
Combined PET/MRI offers a promising approach for early diagnosis of neurodegenerative diseases like dementias and Parkinson disease. This integrated imaging technique aims to provide comprehensive biomarker information for improved diagnostic confidence and patient comfort.
Area of Science:
- Neuroimaging
- Neurology
- Medical Physics
Background:
- Neurodegenerative diseases encompass a range of conditions including dementias, parkinsonian syndromes, Huntington disease, amyotrophic lateral sclerosis, and prion diseases.
- Brain MRI and Positron Emission Tomography (PET) are established tools for diagnosing these conditions, with MRI identifying atrophy patterns and PET detecting neural tissue loss or specific molecular targets.
- The combination of PET and MRI technologies presents an opportunity to enhance early and differential diagnosis.
Purpose of the Study:
- To explore the potential of integrated PET/MRI as a first-line diagnostic tool for neurodegenerative diseases.
- To highlight emerging PET tracers and advanced MRI techniques that can broaden diagnostic capabilities.
- To discuss the future role of combined PET/MRI in clinical practice and research.
Main Methods:
- Review of current literature on the application of combined PET/MRI in neurodegenerative diseases.
- Discussion of existing PET tracers (e.g., [18F]FDG, amyloid, dopaminergic) and emerging tracers (tau, α-synuclein).
- Consideration of advanced MRI techniques (diffusion-tensor imaging, resting-state fMRI, arterial spin labeling).
Main Results:
- Initial evidence suggests that combined PET/MRI can improve early and differential diagnosis of neurodegenerative conditions.
- Emerging PET tracers and MRI techniques hold promise for expanding the diagnostic utility of PET/MRI.
- Accurate PET data attenuation correction remains a technical challenge for PET/MRI systems.
Conclusions:
- Combined PET/MRI has the potential to become a comprehensive, one-stop-shop imaging solution for neurodegenerative diseases, improving diagnostic confidence and patient comfort.
- Further research is needed to validate its efficacy in basic research and drug testing for neurodegenerative diseases.
- Addressing technical challenges like attenuation correction is crucial for widespread clinical adoption.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:30Dementia
The progression of dementia is generally gradual....
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment